Deferiprone

• CAT Number: A000722
• CAS Number: 30652-11-0
• Molecular Formula: C7H9NO2
• Molecular Weight: 139.2
• Purity: ≥95%
• Synonyms: 30652-11-0; 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone; Ferriprox; 3-hydroxy-1,2-dimethylpyridin-4(1H)-one; CP20
• Storage: -20°C
• InChI: 1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3
• InChIKey: TZXKOCQBRNJULO-UHFFFAOYSA-N
• SMILES: CC1=C(C(=O)C=CN1C)O

Deferiprone is a drug that chelates iron and is used to treat thalassaemia major. In 1994 was first approved for use in treating thalassaemia major in 1994 and had been licensed for use in Europe and Asia for many years while awaiting approval in Canada and the United States. On October 14, 2011, it was approved for use in the US under the FDAÂ’s accelerated approval program.

Reference

1: Chan S, Lian Q, Chen MP, Jiang D, Ho JTK, Cheung YF, Chan GCF. Deferiprone
inhibits iron overload-induced tissue factor bearing endothelial microparticle
generation by inhibition oxidative stress induced mitochondrial injury, and
apoptosis. Toxicol Appl Pharmacol. 2017 Nov 10. pii: S0041-008X(17)30442-8. doi:
10.1016/j.taap.2017.11.005. [Epub ahead of print] PubMed PMID: 29132816.

2: Elalfy MS, Adly A, Awad H, Tarif Salam M, Berdoukas V, Tricta F. Safety and
Efficacy of Early Start of Iron Chelation Therapy with Deferiprone in Young
Children Newly Diagnosed with Transfusion-Dependent Thalassemia: A Randomized
Controlled Trial. Am J Hematol. 2017 Nov 9. doi: 10.1002/ajh.24966. [Epub ahead
of print] PubMed PMID: 29119631.

3: Botzenhardt S, Felisi M, Bonifazi D, Del Vecchio GC, Putti MC, Kattamis A,
Ceci A, Wong IC, Neubert A; DEEP Consortium. Long-term safety of deferiprone
treatment in children from the Mediterranean region with beta-thalassaemia major:
the DEEP-3 multi-centre observational safety study. Haematologica. 2017 Oct 27.
pii: haematol.2017.176065. doi: 10.3324/haematol.2017.176065. [Epub ahead of
print] PubMed PMID: 29079595.

4: Salehi S, Saljooghi AS, Badiee S, Moqadam MM. Chelation of Thallium (III) in
Rats Using Combined Deferasirox and Deferiprone Therapy. Toxicol Res. 2017
Oct;33(4):299-304. doi: 10.5487/TR.2017.33.4.299. Epub 2015 Oct 15. PubMed PMID:
29071014; PubMed Central PMCID: PMC5654193.

5: Ansari S, Azarkeivan A, Miri-Aliabad G, Yousefian S, Rostami T. Comparison of
iron chelation effects of deferoxamine, deferasirox, and combination of
deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior.
Caspian J Intern Med. 2017 Summer;8(3):159-164. doi: 10.22088/cjim.8.3.159.
PubMed PMID: 28932366; PubMed Central PMCID: PMC5596185.

6: Richter K, Thomas N, Zhang G, Prestidge CA, Coenye T, Wormald PJ, Vreugde S.
Deferiprone and Gallium-Protoporphyrin Have the Capacity to Potentiate the
Activity of Antibiotics in Staphylococcus aureus Small Colony Variants. Front
Cell Infect Microbiol. 2017 Jun 22;7:280. doi: 10.3389/fcimb.2017.00280.
eCollection 2017. PubMed PMID: 28690982; PubMed Central PMCID: PMC5479885.

7: Carboni E, Tatenhorst L, Tönges L, Barski E, Dambeck V, Bähr M, Lingor P.
Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse
Model of Alpha-Synuclein Aggregation. Neuromolecular Med. 2017
Sep;19(2-3):309-321. doi: 10.1007/s12017-017-8447-9. Epub 2017 Jun 16. PubMed
PMID: 28623611; PubMed Central PMCID: PMC5570801.

8: Martin-Bastida A, Ward RJ, Newbould R, Piccini P, Sharp D, Kabba C, Patel MC,
Spino M, Connelly J, Tricta F, Crichton RR, Dexter DT. Brain iron chelation by
deferiprone in a phase 2 randomised double-blinded placebo controlled clinical
trial in Parkinson/’s disease. Sci Rep. 2017 May 3;7(1):1398. doi:
10.1038/s41598-017-01402-2. PubMed PMID: 28469157; PubMed Central PMCID:
PMC5431100.

9: Belmont A, Kwiatkowski JL. Deferiprone for the treatment of transfusional iron
overload in thalassemia. Expert Rev Hematol. 2017 Jun;10(6):493-503. doi:
10.1080/17474086.2017.1318052. Review. PubMed PMID: 28448199.

10: Richter K, Thomas N, Claeys J, McGuane J, Prestidge CA, Coenye T, Wormald PJ,
Vreugde S. A Topical Hydrogel with Deferiprone and Gallium-Protoporphyrin Targets
Bacterial Iron Metabolism and Has Antibiofilm Activity. Antimicrob Agents
Chemother. 2017 May 24;61(6). pii: e00481-17. doi: 10.1128/AAC.00481-17. Print
2017 Jun. PubMed PMID: 28396543; PubMed Central PMCID: PMC5444117.